Who are Human immunoglobulin intravenous's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/human-immunoglobulin-intravenous.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Human immunoglobulin intravenous — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Human immunoglobulin intravenous (Human immunoglobulin intravenous) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunoglobulin replacement therapy / Passive immunotherapy. Area: Immunology / Infectious Disease / Hematology.

phase 3 Immunoglobulin replacement therapy / Passive immunotherapy Multiple (polyclonal IgG targeting various pathogens and immune targets) Immunology / Infectious Disease / Hematology Small molecule Live · refreshed every 30 min

Target snapshot

Human immunoglobulin intravenous (Human immunoglobulin intravenous) — Green Cross Corporation. Human immunoglobulin intravenous (IVIG) provides passive immunity by delivering pooled antibodies from multiple human donors to neutralize pathogens and modulate immune responses.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Human immunoglobulin intravenous TARGET	Human immunoglobulin intravenous	Green Cross Corporation	phase 3	Immunoglobulin replacement therapy / Passive immunotherapy	Multiple (polyclonal IgG targeting various pathogens and immune targets)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunoglobulin replacement therapy / Passive immunotherapy class)

Green Cross Corporation · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Human immunoglobulin intravenous — Competitive Intelligence Brief. https://druglandscape.com/ci/human-immunoglobulin-intravenous. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab